Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

Fig. 3

DAS28-CRP-adjusted mean change from baseline (per-protocol set). Significant p values compared to placebo are shown (p < 0.05 as one asterisk and p < 0.01 as two asterisks) [150 mg at week 2, p = 0.021; at week 6, p = 0.037; at week 10, p = 0.018; and at week 12, p = 0.005]. DAS28-CRP, 28-joint Disease Activity Score, C-reactive protein version; PBO placebo

Back to article page
\